Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOFIA, Bulgaria--(BUSINESS WIRE)-- #Bulgaria--Takeda been officially recognized as one of the best places to work in Bulgaria for 2021 according to the annual prestigious “Best Places To Work” certification program. Best Places to Work is an international program that provides employers in different countries the opportunity to learn more about engagement and satisfaction of their employees, and honors those who deliver an outstanding work experience. Takeda employees ranked the company high on employee co

Takeda Earns the Best Place To Work Certification in Bulgaria

Anthem

Bausch Health Companies Inc

DuPont de Nemours

Norfolk Southern

Tenet Healthcare

Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

The Top New Buys of Larry Robbins' Firm

Takeda Pharmaceutical Co Ltd (NYSE: TAK) will sell its four non-core type-2 diabetes products (Nesina, Liovel, Inisync, and Zafatek) in Japan to Teijin Pharma Limited, ¥133 billion (roughly $1.25 billion). The portfolio generated total sales of approximately ¥30.8 billion (roughly $290 million) in FY2019.

Takeda Divests Four Diabetes Products In Japan To Teijin Pharma

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”), a Tokyo-based pharmaceutical company, for JPY 133.0 billion, subject to customary legal and regulatory closing conditions. The portfolio to be diveste

Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

MORENO VALLEY, Calif.--(BUSINESS WIRE)--BioLife Plasma Services announces expansion of plasma donation centers into California.

BioLife Plasma Services Announces Expansion of Plasma Donation Centers Into California

Novavax

Takeda Pharmaceutical Co Ltd (NYSE: TAK) said that the first patient had been dosed with Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate (dubbed as TAK-019) in a Japanese clinical trial. The first volunteer was given a Novavax shot in a Phase 1/2 immunogenicity and safety trial of 200 adult volunteers in Japan.

Takeda Doses First Participant In Novavax COVID-19 Vaccine Study In Japan

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax' COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company's Phase 1/2 immunogenicity and safety study of Moderna's COVID-19 vaccine candidate (TAK-919) in Japan. “Early in the pandemic, we made the decision to partner with other companies and lever

Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

Novartis

Pacific Biosciences of California

Regeneron Pharmaceuticals

Roche Holding AG

Teladoc

Thermo Fisher Scientific

Twist Bioscience Corp

Vertex Pharmaceuticals

Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.

ARKG: Precautionary Measures, But Transformational Objectives Remain Intact

When Christophe Weber was appointed CEO of Takeda in 2014, he set out on a mission to transform the 240-year old Japanese pharmaceutical company into a major global player. Over the past six years, that transformation has been progressing at pace, boosted by the US$62 billion acquisition of biopharmaceutical firm Shire in 2019. Insider caught up with Weber to discuss the significance for the Shire acquisition, the challenge of merging two companies from different continents, and how it feels to be one of the very few foreign CEOs in Japan. Insider: When you took over the CEO position at Takeda, what were your main objectives?

First non-Japanese CEO of Takeda has set out 2 objectives: to be an R&D-driven firm and to build global scale

ZURICH--(BUSINESS WIRE)-- #EURORDISAwards2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Engagement in recognition of the company's unwavering commitment to rare disease patients and its comprehensive partnerships with the rare disease patient community. The annual EURORDIS Black Pearl awards ceremony is a celebration of achievements and exceptional work in this space and is held every February marking Rare Disease

Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has announced data from SOLSTICE Phase 3 trial, evaluating maribavir (TAK-620) in hematopoietic cell transplant and solid organ transplant recipients with cytomegalovirus (CMV) infection refractory, with or without resistance, to one or a combination of the conventional antiviral therapies. Overall, more than twice as many (55.7%; n=131/235) patients treated with maribavir achieved confirmed CMV viremia clearance at study week 8 (end of treatment phase), the study's primary endpoint, compared to 23.9% (n=28/117) of those on conventional antiviral therapies.

Takeda's Maribavir Hits Primary Endpoint Goal In Late-Stage Study In Transplant Recipients

OSAKA, Japan--(BUSINESS WIRE)--Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint

Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease. Darvadstrocel received an orphan drug designation in Japan in March 2019.

Takeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease (CD). The application filing included data from two trials, the Japanese Study Darvadstrocel-3002 and the

Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn's Disease

Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q3 2021 Results - Earnings Call Transcript

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020). TAKEDA CHIEF FINANCIAL OFFICER COSTA SAROUKOS commented: “Our third-quarter results demonstrate the resilience of our business model and the depth of our portfolio, with strong growth generated by our 14 global brands. As a values-based and R&D driven biopharmaceutical company, we r

Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS

OSAKA, Japan--(BUSINESS WIRE)--Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza”) for €350 million. TachoSil® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development

Takeda Completes Sale of TachoSil® to Corza Health

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. (“Hypera Pharma”) for a total value of $825 million USD. This divestment agreement was first announced in March 2020. The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American,

Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in previously treated patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) will be presented as a late-breaking oral session at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference o

Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. These actions collectively address 100 percent of Takeda's fiscal year 2019 scope 1, 2, a

Takeda Achieved Carbon Neutrality in 2020

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D ca

Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

Nano-X Imaging

ObsEva

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda was also certified as a Top Employer in four regions and 38 countries. This underscores the company's commitment to creating an exceptional people experience for its global workforce

Takeda Named Global Top Employer for Fourth Consecutive Year

Spherix

EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix's recent report, RealTime Dynamix™:...

Takeda's Entyvio SC and Celltrion's Remsima SC EU5 Launches Have Benefitted from Parent Brand Reputation, New Clinical Data, and COVID-19 Restraints, According to Spherix Global Insights

News for Takeda Pharmaceutical Stock (TAK)